

Chao Wu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7305146/publications.pdf>

Version: 2024-02-01

34
papers

1,286
citations

567281

15
h-index

454955

30
g-index

36
all docs

36
docs citations

36
times ranked

2325
citing authors

#	ARTICLE	IF	CITATIONS
1	A <i>SMAD4</i> -modulated gene profile predicts disease-free survival in stage II and III colorectal cancer. <i>Cancer Reports</i> , 2022, 5, e1423.	1.4	10
2	<i>KRAS</i> Mutants Upregulate Integrin $\alpha 4$ to Promote Invasion and Metastasis in Colorectal Cancer. <i>Molecular Cancer Research</i> , 2022, 20, 1305-1319.	3.4	3
3	Colorectal Cancer Develops Inherent Radiosensitivity That Can Be Predicted Using Patient-Derived Organoids. <i>Cancer Research</i> , 2022, 82, 2298-2312.	0.9	14
4	A Claudin-Based Molecular Signature Identifies High-Risk, Chemoresistant Colorectal Cancer Patients. <i>Cells</i> , 2021, 10, 2211.	4.1	10
5	Rapid interrogation of cancer cell of origin through CRISPR editing. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	12
6	Molecular and phenotypic profiling of colorectal cancer patients in West Africa reveals biological insights. <i>Nature Communications</i> , 2021, 12, 6821.	12.8	15
7	Tumor Microenvironment-Derived <i>NRG1</i> Promotes Antiandrogen Resistance in Prostate Cancer. <i>Cancer Cell</i> , 2020, 38, 279-296.e9.	16.8	135
8	Stomatin-like Protein 2 Promotes Tumor Cell Survival by Activating the JAK2-STAT3-PIM1 Pathway, Suggesting a Novel Therapy in CRC. <i>Molecular Therapy - Oncolytics</i> , 2020, 17, 169-179.	4.4	8
9	Mismatch Repair-Deficient Rectal Cancer and Resistance to Neoadjuvant Chemotherapy. <i>Clinical Cancer Research</i> , 2020, 26, 3271-3279.	7.0	118
10	Loss of <i>CHD1</i> Promotes Heterogeneous Mechanisms of Resistance to AR-Targeted Therapy via Chromatin Dysregulation. <i>Cancer Cell</i> , 2020, 37, 584-598.e11.	16.8	96
11	Genomic stratification beyond <i>Ras/BRAF</i> in colorectal liver metastasis patients treated with hepatic arterial infusion. <i>Cancer Medicine</i> , 2019, 8, 6538-6548.	2.8	8
12	A rectal cancer organoid platform to study individual responses to chemoradiation. <i>Nature Medicine</i> , 2019, 25, 1607-1614.	30.7	320
13	<i>SMAD4</i> Loss in Colorectal Cancer Patients Correlates with Recurrence, Loss of Immune Infiltrate, and Chemoresistance. <i>Clinical Cancer Research</i> , 2019, 25, 1948-1956.	7.0	71
14	Abstract 111: Tumor microenvironment derived <i>NRG1</i> promotes antiandrogen resistance in prostate cancer. , 2019, , .		0
15	Epithelial <i>Smad4</i> Deletion Up-Regulates Inflammation and Promotes Inflammation-Associated Cancer. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2018, 6, 257-276.	4.5	50
16	<i>SMAD4</i> loss in colorectal cancer: Correlation with recurrence, chemoresistance, and immune infiltrate.. <i>Journal of Clinical Oncology</i> , 2017, 35, 587-587.	1.6	5
17	Opposing influence of intracellular and membrane thiols on the toxicity of reducible polycations. <i>Biomaterials</i> , 2013, 34, 8843-8850.	11.4	22
18	Synthesis of Bisethyl norspermine Lipid Prodrug as Gene Delivery Vector Targeting Polyamine Metabolism in Breast Cancer. <i>Molecular Pharmaceutics</i> , 2012, 9, 1654-1664.	4.6	18

#	ARTICLE	IF	CITATIONS
19	Bisethylnorspermine Lipopolyamine as Potential Delivery Vector for Combination Drug/Gene Anticancer Therapies. <i>Pharmaceutical Research</i> , 2010, 27, 1927-1938.	3.5	6
20	Effect of innate glutathione levels on activity of redox-responsive gene delivery vectors. <i>Journal of Controlled Release</i> , 2010, 141, 77-84.	9.9	93
21	Effects of monoamine oxidase inhibitor and cytochrome P450 2D6 status on 5-methoxy-N,N-dimethyltryptamine metabolism and pharmacokinetics. <i>Biochemical Pharmacology</i> , 2010, 80, 122-128.	4.4	31
22	Methylation of 5-Amino-3-methylthio-1 H-pyrazole Derivatives and Two Related Crystal Structures. <i>Chinese Journal of Chemistry</i> , 2010, 22, 194-198.	4.9	7
23	Effects of CYP2D6 status on harmaline metabolism, pharmacokinetics and pharmacodynamics, and a pharmacogenetics-based pharmacokinetic model. <i>Biochemical Pharmacology</i> , 2009, 78, 617-624.	4.4	44
24	Evaluation of Pharmacokinetics of Bioreducible Gene Delivery Vectors by Real-time PCR. <i>Pharmaceutical Research</i> , 2009, 26, 1581-1589.	3.5	24
25	Cyclic RGD-targeting of reversibly stabilized DNA nanoparticles enhances cell uptake and transfection in vitro. <i>Journal of Drug Targeting</i> , 2009, 17, 364-373.	4.4	22
26	Bioreducible Hyperbranched Poly(amido amine)s for Gene Delivery. <i>Biomacromolecules</i> , 2009, 10, 2921-2927.	5.4	112
27	Design, Synthesis, and Quantitative Structure~Activity Relationship Study of Herbicidal Analogues of Pyrazolo[5,1-d][1,2,3,5]tetrazin-4(3H)ones. <i>Journal of Agricultural and Food Chemistry</i> , 2007, 55, 1364-1369.	5.2	18
28	Synthesis of a small library containing substituted pyrazoles. <i>Arkivoc</i> , 2005, 2005, 59-67.	0.5	10
29	Three Trifluoromethyl-Substituted Protoporphyrinogen IX Oxidase Inhibitors.. <i>ChemInform</i> , 2005, 36, no.	0.0	0
30	Two isomeric 2-[4-chloro-2-fluoro-5-(prop-2-ynoxy)phenyl]hexahydroisindole-1,3-dione compounds. <i>Acta Crystallographica Section C: Crystal Structure Communications</i> , 2005, 61, o114-o117.	0.4	0
31	Three trifluoromethyl-substituted protoporphyrinogen IX oxidase inhibitors. <i>Acta Crystallographica Section C: Crystal Structure Communications</i> , 2005, 61, o122-o126.	0.4	2
32	Ethyl 5-amino-3-(4,6-dimethylpyrimidin-2-ylamino)-1-methyl-1H-pyrazole-4-carboxylate and ethyl 5-amino-3-(4,6-dimethylpyrimidin-2-ylamino)-1-(2-nitrophenylsulfonyl)-1H-pyrazole-4-carboxylate. <i>Acta Crystallographica Section C: Crystal Structure Communications</i> , 2005, 61, o281-o283.	0.4	0
33	5-Methyl-2-methylsulfonyl-7-phenylpyrazolo[1,5-a]pyrimidine-3-carbonitrile. <i>Acta Crystallographica Section E: Structure Reports Online</i> , 2005, 61, o2506-o2507.	0.2	1
34	A Facile Synthesis of Novel Herbicidal 1-Phenyl-piperazine-2,6-diones. <i>Molecules</i> , 2005, 10, 1119-1125.	3.8	1